Agrawal Anurag, Mabalirajan Ulaganathan, Ram Arjun, Ghosh Balaram
Molecular Immunology and Immunogenetics Laboratory, Institute of Genomics and Integrative Biology, University of Delhi, Delhi-110 007, India.
Recent Pat Inflamm Allergy Drug Discov. 2007 Nov;1(3):188-92. doi: 10.2174/187221307782418865.
Many obstructive airway disorders such as cystic fibrosis, asthma, and chronic obstructive pulmonary disease (COPD) are characterized by mucous metaplasia of the airway epithelium and chronic mucus hypersecretion. Airway occlusion by mucus plugging has been reported in many cases of fatal asthma and conventional mucolytic therapies have been unable to significantly affect mucus-related airway obstruction. Recently, for the first time, direct evidence was presented for improvement of mucus related airway obstruction in a murine model of asthma, highlighting the potential usefulness of therapeutically targeting mucus hypersecretion. We review the emerging targets for inhibition of mucus hypersecretion and discuss some of the recent published scientific literature and patent applications in this field, to provide a framework for further drug discovery in mucus modulation.
许多阻塞性气道疾病，如囊性纤维化、哮喘和慢性阻塞性肺疾病（COPD），其特征为气道上皮的黏液化生和慢性黏液分泌过多。在许多致命性哮喘病例中都有黏液堵塞导致气道阻塞的报道，而传统的黏液溶解疗法无法显著改善与黏液相关的气道阻塞。最近，首次在哮喘小鼠模型中提供了改善与黏液相关的气道阻塞的直接证据，突出了治疗性靶向黏液分泌过多的潜在效用。我们综述了抑制黏液分泌过多的新靶点，并讨论了该领域最近发表的一些科学文献和专利申请，以提供一个在黏液调节方面进一步药物研发的框架。
